RT Journal Article
SR Electronic
T1 Machine Learning for Pattern Detection in Cochlear Implant FDA Adverse Event Reports
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.30.20086660
DO 10.1101/2020.04.30.20086660
A1 Matthew G. Crowson
A1 Amr Hamour
A1 Vincent Lin
A1 Joseph M. Chen
A1 Timothy C. Y. Chan
YR 2020
UL http://medrxiv.org/content/early/2020/05/05/2020.04.30.20086660.abstract
AB Importance The United States Food & Drug Administration (FDA) passively monitors medical device performance and safety through submitted medical device reports (MDRs) in the Manufacturer and User Facility Device Experience (MAUDE) database. These databases can be analyzed for patterns and novel opportunities for improving patient safety and/or device design.Objectives The objective of this analysis was to use supervised machine learning to explore patterns in reported adverse events involving cochlear implants.Design The MDRs for the top three CI manufacturers by volume from January 1st 2009 to August 30th 2019 were retained for the analysis. Natural language processing was used to measure the importance of specific words. Four supervised machine learning algorithms were used to predict which adverse event narrative description pattern corresponded with a specific cochlear implant manufacturer and adverse event type - injury, malfunction, or death.Setting U.S. government public database.Participants Adult and pediatric cochlear patients.Exposure Surgical placement of a cochlear implant.Main Outcome Measure Machine learning model classification prediction accuracy (% correct predictions).Results 27,511 adverse events related to cochlear implant devices were submitted to the MAUDE database during the study period. Most adverse events involved patient injury (n = 16,736), followed by device malfunction (n = 10,760), and death (n = 16). Submissions to the database were dominated by Cochlear Corporation (n = 13,897), followed by MedEL (n = 7,125), and Advanced Bionics (n = 6,489). The random forest, linear SVC, naïve Bayes and logistic algorithms were able to predict the specific CI manufacturer based on the adverse event narrative with an average accuracy of 74.8%, 86.0%, 88.5% and 88.6%, respectively.Conclusions & Relevance Using supervised machine learning algorithms, our classification models were able to predict the CI manufacturer and event type with high accuracy based on patterns in adverse event text descriptions.Level of evidence 3Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in the FDA MAUDE database at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm.